急性髓系白血病靶向治疗二十年回顾
Precision medicine is gaining importance in the treatment of acute myeloid leukemia (AML). Objectively reviewing past and current knowledge aids guiding future research.…
要点
- 2000-2020年间AML靶向治疗II期试验涉及167种药物、96个靶点,共397项。
- 获批药物中无一项在批准时评估生活质量,3/8尚未显示总生存获益。
核心结论
- AML靶向治疗研究的转化效率较低,患者获益有限。
- 未来试验不应忽视非靶向药物,并应优先研究能预测患者福祉的终点。
研究设计与样本
- 综述分析了2000年1月至2020年9月间所有AML靶向治疗的II期和III期试验。
- 共纳入167种药物、96个靶点、397项II期试验,并追踪药物向III期及FDA批准的进展。
主要发现
- 重新定位药物较原研AML药物更少推进至临床开发后期。
- II期试验中最常用的主要终点为复合缓解率。
- 8种FDA批准药物中,无一项在批准时评估生活质量,3种尚未显示总生存获益。
临床怎么用
- 临床决策时应关注靶向药物是否已显示总生存或生活质量获益。
- 对尚未证实生存获益的获批靶向药物需谨慎评估其风险获益比。
局限性
- 综述未报告各试验的具体样本量、效应值及统计学显著性。
- 仅纳入II期和III期试验,未涉及早期或观察性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Precision medicine is gaining importance in the treatment of acute myeloid leukemia (AML). Objectively reviewing past and current knowledge aids guiding future research. Therefore, we provide a complete overview of all phase II and phase III trials investigating targeted therapies in AML and their primary endpoints over the past two decades in perspective of their clinical benefit. We assessed whether drugs were primarily designed to treat AML or were repurposed and how successful they were based on progression of distinct drugs from phase II to phase III to FDA-approval. Between January 2000 and September 2020, 167 agents with 96 targets were investigated in 397 phase II trials. Twenty-eight agents were steered towards phase III, after three phase II trials on average. Repurposed drugs less often advanced in clinical development than drugs primarily developed for AML. Composite responses were the most prevalent primary endpoints in phase II. Of the eight FDA-approved drugs, none investigated quality of life at time of approval, and three out of eight have yet to show benefit in overall survival. Returns on targeted therapy research remain lean for AML patients. Future trials should not overlook non-targeted agents and foremost study endpoints proven to predict patient well-being.
引用
- Cucchi DGJ, Polak TB, Ossenkoppele GJ, et al. Two decades of targeted therapies in acute myeloid leukemia. Leukemia. 2021. PMID: 33589753. doi:10.1038/s41375-021-01164-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。